drug

OXCARBAZEPINE

Marketedupdated 2mo ago

by Aucta Pharmaceuticals Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for epilepsy and seizure and 7 investigational indications.

all catalysts(64)

approval · 64

Jan 14, 2000

approval

26y ago

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

OXCARBAZEPINE — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

OXCARBAZEPINE

→

view all 64 catalysts →

News(0)

no news has mentioned this drug yet

brand

OXCARBAZEPINE

generic

OXCARBAZEPINE

MOA

12.1 Mechanism of Action The pharmacological activity of TRILEPTAL is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine [ see Clinical Pharmacology (12.3) ]. The precise mechanism by which oxcarbazepine and MHD exert their anti-seizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug. No significant interactions of oxcarbazepine or MHD with brain neurotransmitter or modulator receptor sites have been demonstrated.

indication

Partial Seizure

phase

marketed

OXCARBAZEPINE

all catalysts(64)

News(0)

Report a data issue

Patent cliff

patents (33)

comments(0)

🐶 often sniffed alongside

Trials studying OXCARBAZEPINE